Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer

Human Gene Therapy

Volumn 11, Issue 17, 2000, Pages 2377-2387

  Parker, L L ^a   Do, M T ^a   Westwood, J A ^a   Wunderlich, J R ^a   Dudley, M E ^a   Rosenberg, S A ^a   Hwu, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE BINDING PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; RECEPTOR PROTEIN; RECEPTOR PROTEIN MOV GAMMA; UNCLASSIFIED DRUG; CD3 ANTIGEN; CYTOKINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY MOV18; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL STIMULATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; OVARY CANCER; T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CULTURE MEDIUM; FEMALE; GENE THERAPY; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; METHODOLOGY; OVARY TUMOR; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; RADIATION EXPOSURE; REFERENCE VALUE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CULTURE MEDIA; CYTOKINES; FEMALE; GENE THERAPY; HUMANS; INTERLEUKIN-2; MELANOMA; OVARIAN NEOPLASMS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; REFERENCE VALUES; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034693937     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303400750038480     Document Type: Article

References (39)

1. + tumor-infiltrating lymphocytes
2. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice
3. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
4. In vivo migration and function of transferred HIV-1 specific cytotoxic T cells
5. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
6. Type 1 and type 2: A fundamental dichotomy for all T-cell subsets
7. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein
8. Lymphocytes as cellular vehicles for gene therapy in mouse and man
9. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene
10. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges
11. T cell clones from melanoma patients immunized against an anchor-modified gpl00 peptide display discordant effector phenotypes
12. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
13. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
14. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
15. The central role of CD4(+) T cells in the antitumor immune response
16. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
17. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
18. High efficiency gene transfer into primary human tumor explants without cell selection
19. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients
20. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production
21. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity
22. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
23. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
24. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response
25. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors
26. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
27. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
28. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
29. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
30. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
31. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis
32. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
33. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors
34. IL-2 gene therapy of advanced lung cancer patients
35. CD4 T cells and their role in antitumor immune responses
36. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
37. Gene-based strategies for the immunotherapy of cancer
38. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens
39. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor